ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc. (NASDAQ:ETRM), a developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced interim clinical results for the company’s Maestro™ RF2 System. The Maestro RF2 System is currently being evaluated in 33 obese patients outside the United States in the VBLOC-RF2 clinical feasibility study of the company’s proprietary VBLOC™ vagal blocking therapy.
